tbuckley/cabot-search huggingface dataset:
Disseminated histoplasmosis partially mimicking a dermatomyositis in a patient with rheumatoid arthritis
Authors: A.S. Dussouil, J. Allardet-Servent, L. Dunogeant, J.L. Grauer, S. Ranque, V. Nasser
Journal: British Journal of Dermatology (2015)

Journal Article Disseminated histoplasmosis partially mimicking a dermatomyositis in a patient with rheumatoid arthritis Get access A.S. Dussouil, A.S. Dussouil Service de Médecine Interne et Rhumatologie Centre Hospitalier du Pays d'Aix Aix en Provence France Correspondence Anne‐Sophie Dussouil. E‐mail: annesophie.dussouil@gmail.com Search for other works by this author on: Oxford Academic Google Scholar J. Allardet‐Servent, J. Allardet‐Servent Service de Réanimation Hôpital Européen Marseille France Search for other works by this author on: Oxford Academic Google Scholar L. Dunogeant, L. Dunogeant Service de Médecine Interne et Rhumatologie Centre Hospitalier du Pays d'Aix Aix en Provence France Search for other works by this author on: Oxford Academic Google Scholar J.L. Grauer, J.L. Grauer Service de Médecine Interne et Rhumatologie Centre Hospitalier du Pays d'Aix Aix en Provence France Search for other works by this author on: Oxford Academic Google Scholar S. Ranque, S. Ranque Service de Parasitologie et Mycologie Assistance Publique des Hôpitaux de Marseille Hôpital de la Timone Marseille France Search for other works by this author on: Oxford Academic Google Scholar V. Nasser V. Nasser Service de Médecine Interne et Rhumatologie Centre Hospitalier du Pays d'Aix Aix en Provence France Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 173, Issue 3, 1 September 2015, Pages 797–800, https://doi.org/10.1111/bjd.13876 Published: 01 September 2015
Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts
Authors: Jerome Paggetti, Franziska Haderk, Martina Seiffert, Bassam Janji, Ute Distler, Wim Ammerlaan, Yeoun Jin Kim, Julien Adam, Peter Lichter, Eric Solary, Guy Berchem, Etienne Moussay
Journal: Blood (2015)
The anti-vascular and anti-tumor response of human lung cancer growing orthotopically in mice to AEE788, a tyrosine kinase inhibitor of EGFR and VEGFR, is dependent upon EGF/TGFα expression
Authors: Wenjuan Wu, Robert Langley, Cheryl H. Baker, Michael S. O’Reilly, Isaiah J. Fidler, Roy S. Herbst
Journal: Cancer Research (2005)

3031  Introduction: Targeting of EGFR has been extensively studied in lung cancer; yet, clinical data show that only a fraction of patients can respond to EGFR inhibitors. The development and validation of strategies to identify patients likely to benefit from these agents is therefore of critical importance. We hypothesized that the expression of EGF/TGFα by tumors is needed for activation of EGFR in both tumor (autocrine) and tumor-associated endothelial (paracrine) cells and would thus be required for an anti-tumor and anti-vascular response to EGFR signal blockade. Methods: The human lung adenocarcinoma cell lines NCIH441 (EGF/TGFα+/EGFR+) and PC14PE6 (EGF/TGFα-/EGFR+) were injected into the lungs of mice. Once tumors formed, mice were randomized to treatment with AEE788 or vehicle. When control mice became moribund, animals were killed and assessed for tumor size, pleural effusion, metastasis, and immunohistochemical studies. The EGFR nucleotide sequence was analyzed in H441 and PC14PE6 cell lines. Results: EGFR was found to be wild type in both H441 and PC14PE6 cells. Treatment of mice bearing H441 lung tumors with AEE788 resulted in a significant (p
Abstract 12898: Serum Vascular Endothelial Growth Factor-C Levels are Inversely Associated With Major Adverse Cardiovascular Events in Patients With Arteriosclerotic Obliterans
Authors: Nobutoyo Masunaga, Hiromichi Wada, Masaharu Akao, Shuichi Ura, Akira Yamada, Mitsuru Abe, Mitsuru Ishii, Takashi Unoki, Moritake iguchi, Yugo Yamashita, Yasuhuro Hamatani, Hisashi Ogawa, Daisuke Takagi, Noriko Satoh-Asahara, Akira Shimatu, Koji Hasegawa
Journal: Circulation (2014)

Background: Vascular endothelial growth factor-C (VEGF-C), a homologue of VEGF family, plays a key role in lymphangiogenesis. Recently, we demonstrated that VEGF-C is closely associated with dyslipidemia and atherosclerosis. However, the relationship between serum VEGF-C levels and cardiovascular events in patients with atherosclerotic disease is unknown. Methods and Results: We performed a prospective cohort study involving a total of 209 patients with arteriosclerotic obliterans (ASO) (age, 73±8 y [SD]; male, 75%; hypertension, 88%; diabetes, 69%; dyslipidemia, 72%; history of smoking, 76%; Fontaine class, 2.1±0.8). Serum levels of VEGF-C, VEGF-A and high-sensitivity C-reactive protein (hsCRP) were determined employing specific enzyme-linked immunosorbent assays. The primary outcome was major adverse cardiac events (MACEs) defined as all-cause mortality, hospitalization due to acute coronary syndrome, stroke, congestive heart failure, aortic disease, and coronary/peripheral revascularization. Patients were followed up over a 4 year period. The median follow-up was 484 (IQR, 220-955) days. During the follow-up period, MACEs developed in a total of 86 patients (41.1 %). Patients were divided into two groups based on the median of each biomarker. In Kaplan-Meier analyses, low-VEGF-C (P=0.014, by log-rank test), but not high-hsCRP or high-VEGF-A, was significantly associated with MACEs. Multivariate Cox proportional hazard analyses revealed that serum levels of VEGF-C (hazard ratio [HR], 0.79 [per 1-SD increase]; 95% confidence interval [CI], 0.63-0.99; P=0.04), but not hsCRP or VEGF-A, were inversely and significantly associated with MACEs after adjustment for age, gender, and established risk factors. Finally, we performed stepwise Cox proportional hazard analysis including data on age, gender, established risk factors, Fontaine class and serum levels of hsCRP, VEGF-A and VEGF-C. Notably, Fontaine class (HR, 1.4; 95% CI, 1.1-1.8; P=0.002) and the VEGF-C level (HR [per 1-SD increase], 0.80; 95% CI, 0.64-0.99; P=0.045), but not other parameters, were independent predictors of MACEs. Conclusions: A low VEGF-C value may serve as a predictive marker of cardiovascular events in patients with ASO.
Challenges for psychiatry: delivering the Mental Health Declaration for Europe.
Authors: Matt Muijen
Journal: World Psychiatry (2006)

Mental health care is in the process of transformation across the European Region, due to a combination of recognition of disease burden, poor treatment conditions and demand from clinicians and the public. This transformation affects the scope of mental health, increasingly including promotion and prevention, and the structure and process of care, shifting to community based delivery. Many psychiatrists are in leadership positions, able to influence policies and strategies. But their work is also seriously affected by the consequences of these policies. New roles and responsibilities of all members of a multi-disciplinary team need to be planned, and education and training have to be designed to prepare professionals to deal with expectations and demands. Psychiatrists face major challenges, since their complex roles are affected in multiple ways by the psychiatric and general health system. Some of these challenges can be addressed by the psychiatric profession and their partners, including patient and family organizations; others require wide ranging changes in attitude and system design.
Abstract 16473: Increase in Left Ventricular Mass and Decrease in 3d Global Strain After Right Ventricular Pacing is Determined by the Development of Pacing-Induced Systolic Dyssynchrony - A Study by Novel 3-Dimensional Approach
Authors: Fang Fang, Xiu-xia Luo, Ling Ji, Qing Zhang, Yujia Liang, Chunyan Ma, Xin Jiang, Cheuk-Man Yu
Journal: Circulation (2014)

Aim: The detrimental effect of conventional right ventricular apical (RVA) pacing on reduction of left ventricular (LV) systolic function has been demonstrated in patients with normal ejection fraction (EF). However, little is known whether there is alteration of LV mass, i.e., true LV adverse remodeling, and its relationship with pacing-induced systolic dyssynchrony.

Methods: Eighty-seven patients (71±11 years, 46 males) with high-grade atrioventricular block and preserved EF (mean: 64±7%) were prospectively enrolled at baseline, and 1 year after RVA pacing. Three-dimensional (3D) echocardiography and tissue Doppler imaging (TDI) was performed (GE, Horten, Norway) to assess LV mass, global 3D deformation (area strain) and systolic dyssynchrony [standard deviation of time to peak systolic velocity of 12 LV segments (Ts-SD) ≥33ms].

Results: At 1 year, LV mass increased significantly (133±22 vs. 146±35 g, p=0.028) with decreased area strain (31±6 vs. 24±5%, p 55 years) [hazard ratio (HR) =2.83, p=0.05] and presence of systolic dyssynchrony (HR=3.27, p=0.01). In multivariate analysis, only systolic dyssynchrony remained as independent determinant for increase in LV mass (HR=3.19, p=0.01).

Conclusion: In patients who developed RVA pacing-induced systolic dyssynchrony, there was increase in LV mass and impairment of LV systolic strain which underpin the development of true LV adverse remodeling.

   ![][1]  [1]: /embed/graphic-1.gif
Family planning needs of female chronic psychiatric outpatients
Authors: J H Coverdale, J A Aruffo
Journal: American Journal of Psychiatry (1989)

The authors investigated the pregnancy outcomes, contraceptive behavior, and contraceptive needs of 80 female chronic psychiatric outpatients. Thirty-one percent of the patients reported they had had induced abortions. Of 75 children born, 60% were being reared by people other than the mothers. Thirty-three percent of the patients who had had intercourse during the preceding year and had not wanted to become pregnant reported not having used contraception at the time of last intercourse. The authors discuss the special contraceptive needs of chronic psychiatric patients and encourage psychiatrists to inquire about patients' family planning practices.
Surgery of relapsed hydatid disease of lungs
Authors: Davlat Maksumov, Bahrom Amanov, Rustem Hayaliev
Journal: European Respiratory Journal (2011)

The surgical treatment of hydatid disease of lungs is unique and the most radical, however and after operations the development of relapses is possible. On the data of the literature the relapse of hydatid disease after surgical treatment does not tend to decrease and changes from 3% up to 54%.

In the department of surgery of lungs and mediastinum Republican Specialized Center of Surgery named after acad. V.Vahidov from 1975 to 2009yy there were on treatment 2600 patients with hydatid disease of lungs. From 2600 operated patients concerning the various forms of hydatid disease of lungs relapse of disease from 1 to 7 years we observed in 160 (6,5%) patients. From them: men - 93 (58,1%), women - 67 (41,9%). The age of the patients varied from 10 to 70 years. From 160 patients 130 (81,25%) undergone operations, not operated 30 (18,7%) - the reason was disseminated process, wide distribution of hydatid cysts. 152 (95%) patients were performed organsaving operation, 8 (5%) patients underwent resections.

In the postoperative period albendazole was administered in a doze 10-12 mg/kg/day, quantity of courses depended on the form of a defeat.
Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures
Authors: Nathan P. Clark, Daniel M. Witt, Loren E. Davies, Edward M. Saito, Kathleen H. McCool, James D. Douketis, Kelli R. Metz, Thomas Delate
Journal: JAMA Internal Medicine (2015)

The risk of bleeding and recurrent venous thromboembolism (VTE) among patients receiving long-term warfarin sodium therapy for secondary VTE prevention who require temporary interruption of anticoagulant therapy for surgery or invasive diagnostic procedures has not been adequately described.To describe the rates of clinically relevant bleeding and recurrent VTE among patients in whom warfarin therapy is interrupted for invasive procedures and compare these rates among patients who did and did not receive bridge therapy.A retrospective cohort study was conducted at Kaiser Permanente Colorado, an integrated health care delivery system. Patients in whom warfarin therapy was interrupted for invasive diagnostic or surgical procedures between January 1, 2006, and March 31, 2012, were identified via queries of administrative data sets. A total of 1812 procedures in 1178 patients met inclusion criteria. Data on outcomes and exposures were collected between June 1, 2005, and April 30, 2012.Use of bridge therapy vs no bridge therapy during warfarin interruption.Thirty-day clinically relevant bleeding, recurrent VTE, and all-cause mortality. Outcomes were verified via manual review of medical records.Among the 1178 patients, the mean (SD) age was 66.1 (12.7) years, 830 procedures (45.8%) were in men, and the most common indication for warfarin therapy was deep vein thrombosis (56.3%). Most patients were considered to be at low risk for VTE recurrence at the time of warfarin interruption (1431 procedures [79.0%]) according to the consensus guidelines of the American College of Chest Physicians. Clinically relevant bleeding within 30 days after the procedure in the bridge therapy and non-bridge therapy groups occurred in 15 patients (2.7%) and 2 patients (0.2%), respectively (hazard ratio, 17.2; 95% CI, 3.9-75.1). There was no significant difference in the rate of recurrent VTE between the bridge and non-bridge therapy groups (0 vs 3; P = .56). No deaths occurred in either group.Bridge therapy was associated with an increased risk of bleeding during warfarin therapy interruption for invasive procedures in patients receiving treatment for a history of VTE and is likely unnecessary for most of these patients. Further research is needed to identify patient- and procedure-related characteristics associated with a high risk of perioperative VTE recurrence during warfarin therapy interruption.
Protein microarrays identify disease-specific anti-cytokine autoantibody profiles in the landscape of immunodeficiency
Authors: Jacob M Rosenberg, Jordan V Price, Gabriela Barcenas-Morales, Lourdes Ceron-Gutierrez, Sophie Davies, Dinakantha S Kumararatne, Rainer Döffinger, Paul J Utz
Journal: Journal of Allergy and Clinical Immunology (2015)
Subcutaneous ventricular catheter reservoir and ventriculoperitoneal drain-related infections in preterm infants and young children
Authors: N. Bruinsma, E.E. Stobberingh, M.J.H.M. Herpers, J.S.H. Vles, B.J. Weber, D.A.W.D. Gavilanes
Journal: Clinical Microbiology and Infection (2000)
An international association between Helicobacter pylori infection and gastric cancer
Authors: D Forman, M Coleman, Gui De Backer, J Eider, H Moller, Lc Damotta, P Roy, L Abid, A Tjonneland, H Boeing, T Haubrich, J Wahrendorf, O Manousos, H Tulinius, H Ogmundsdottir, D Palli, F Cipriani, A Fukao, S Tsugane, Y Miyajima, W Zatonski, J Tyczynski, J Calheiros, Mp Zakelj, M Potocnik, P Webb, T Knight, A Wilson, S Kaye, J Potter
Journal: The Lancet (1993)
Pemetrexed vs docetaxel for non-small cell lung cancer (NSCLC): Could vitamin supplementation affect docetaxel survival? An exploratory analysis
Authors: F. Fossella, C. Obasaju, S. Paul
Journal: Journal of Clinical Oncology (2004)

7131 Background: Based on randomized phase III studies, docetaxel is standard second-line treatment for NSCLC. In a recent comparison of pemetrexed, a novel multitargeted antifolate, versus docetaxel in previously treated patients (pts) with advanced NSCLC, survival time with pemetrexed therapy was similar to docetaxel (median 8.3 vs 7.9 months). Pts (N=571) were randomized to receive either pemetrexed (500 mg/m2 IV), supplemented with vitamin B12 injections and oral folic acid, or docetaxel (75 mg/m2 IV) on day 1 of 21-day cycles. This exploratory analysis compares overall survival time between two subgroups of pts on docetaxel therapy, those with and without patient reported vitamin supplementation, to evaluate the potential effect of supplementation on survival. In addition, a second analysis compared the survival of supplemented docetaxel pts with those treated with pemetrexed. Methods: Survival analyses were performed using the Kaplan-Meier method in all the subsets of pts. Results: Although not required by the protocol, 82 pts in the docetaxel arm reported receiving folic acid and/or vitamin B12 as concomitant medication while on study and were included in this analysis. Baseline characteristics were well-balanced between the docetaxel subgroups with the exception of Stage and ECOG performance status (PS). Conclusions: In the original study, overall survival was similar for both treatment arms. In this evaluation, these results provide no evidence that the overall survival in docetaxel treated pts is influenced by vitamin supplementation status. It does not appear that the survival result observed between pemetrexed and docetaxel would have been affected if all pts in the docetaxel arm had been supplemented with folic acid and B12. *Comparing pemetrexed supplemented with docetaxel supplemented Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly
Abstract 18224: Patient and Caregiver Perceptions of Living with a Left Ventricular Assist Device as Destination Therapy
Authors: Lisa A Kitko, John P Boehmer, Judith E Hupcey
Journal: Circulation (2011)

LVADs have been shown to improve survival in patients with end-stage heart failure. Initially developed as a bridge to transplantation, LVADs are now implanted permanently as destination treatment (DT) or end of life treatment. While the number of LVAD-DT implants is increasing, there remains a paucity of research on the experiences of patients and their caregivers and the impact of living with this device. The objective of this study was to examine changes in the perception of burden of treatment for patients and caregivers prior to and following the LVAD implant. Methods: A sample of 25 patients and caregivers one month to 2-years post-LVAD implant were surveyed using a one item (rating 0-100) visual analog scale (VAS) with “0” being “not at all burdened” to “100” being “extremely burdened.” Patients and caregivers were asked to rate their perceptions of the burden of treatment (eg, medications, diet, daily weights, appointments) prior to the implant and their present perceptions post-LVAD implant. Findings: For the majority of patients, the perceptions of the burden of treatment dramatically decreased post-LVAD implant, with no trend based on time since implant. Conversely, caregivers continued to rate their perceptions of the burden of treatment post-LVAD implant at pre-implant levels or higher. Conclusions: A disparity exists in the perception of burden post-LVAD implant between patients and caregivers. Patients post-LVAD-DT implant rate the burden of treatment lower than caregivers. Caregivers continue to perceive increased rates of the burden of treatment related to general care (eg., diet, medications) and the care required to maintain the LVAD-DT such as battery support, uncertainty related to device failure, and drive line care. Implications: The incongruent perceptions of the burden of treatment post-LVAD-DT between patients and caregivers has important practice implications. Caregivers are the main source of support for these patients and need to be considered as both co-providers and co-recipients of care. Thus caregivers’ needs must also be assessed and interventions targeted to improve the experiences of both patients and caregivers as they live through this end-of-life trajectory.
Abstract #LB-214: Efficacy of PI3K inhibitors to PI3K mutants in enzyme and cell levels
Authors: Shingo Dan, Hironobu Sugita, Kanami Yamazaki, Takao Yamori
Journal: Cancer Research (2009)

PIK3CA, which encodes catalytic subunit (p110\#945;) of PI3K\#945;, has been reported to be frequently activated in cancer by somatic mutation and gene amplification. Furthermore, loss of PTEN function is often observed in cancer. Thus, PI3K pathway has been considered a promising target for cancer therapy. Recently, PI3K inhibitors harboring antitumor activity without severe toxicity, including ZSTK474 and NVP-BEZ235, have been developed. These drugs were shown to inhibit tumor proliferation in vivo and in vitro. However, extensive evaluation of their efficacy to PI3K carrying a gain-of-function mutation has not yet been accomplished. To examine relationship between mutation status of p110\#945; and the efficacy to PI3K inhibitors in enzyme and cell levels, we used a panel of 39 human cancer cell lines (JFCR39). We investigated the mutation status of PIK3CA and the efficacy of PI3K inhibitors across the JFCR39 and identified seven cell lines harboring PIK3CA mutations. Most mutations were located in hotspot (E545K and H1047R), but some of them were in other residues (I391M, P449T, D549N and L719F). To evaluate the efficacy of PI3K inhibitors to PI3K mutants, we constructed a new assay system to quantitatively measure PI3K activity by using recombinant p110\#945; proteins produced in human 293T cells in combination with homogeneous time-resolved fluorescence (HTRF) assay. We found that four mutants including P449T (2.3-fold), E545K (8.5-fold), E545K/D549N (6.3-fold) and H1047R (5.8-fold) exhibited enhanced kinase activities compared to wild-type p110\#945;. Both ZSTK474 and NVP-BEZ235 inhibited the kinase activity of E545K and H1047R mutant as well as wild-type PI3K. Then, we examined the effects of the PI3K inhibitors on the cell lines with or without PIK3CA mutation. No significant correlation was observed between the drug efficacy and the mutation status of PIK3CA. These results indicated that ZSTK474 and NVP-BEZ235 were effective to gain-of-function mutants of p110\#945; in both enzyme and cell levels. Therefore, these PI3K inhibitors may have therapeutic efficacy against the cancers with PIK3CA mutation.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-214.
Abstract 15051: Left Ventricular Dilatation Improves Survival in Patients with Severe Sepsis
Authors: Monique S Tanna, Darlene LeFrancois, Christopher Velez, Nadia Ali, Elizabeth Zheng, Sharon Leung
Journal: Circulation (2012)

OBJECTIVE: The hallmark of sepsis-induced myocardial dysfunction is the development of acute left ventricular (LV) dysfunction, with a normal or increased cardiac output. This preservation of cardi...